Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836461 | 0.86 | SMN1; SMN2 (0.44) | ALDH1A1POLBKDM4EMAPTKMT2A | |
| SCHEMBL5390665 | 0.85 | TP53 (0.47) | ALDH1A1POLBKDM4EMAPTKMT2A | |
| SCHEMBL6500690 | 0.85 | AR (0.44) | ALDH1A1ARPTGDR2 | |
| SCHEMBL7478866 | 0.82 | ALOX5 (0.41) | ALDH1A1POLBKDM4EMAPTLMNA | |
| SCHEMBL5390662 | 0.79 | TP53 (0.48) | ALDH1A1POLBKDM4EMAPTKMT2A | |
| SCHEMBL6494601 | 0.77 | PDE4D (0.55) | ALDH1A1POLBKDM4EMAPTKMT2A | |
| SCHEMBL3835827 | 0.75 | SMN1; SMN2 (0.46) | ALDH1A1POLBKDM4EKMT2AHSD17B10 | |
| SCHEMBL5376137 | 0.74 | SMN1; SMN2 (0.39) | ALDH1A1POLBKDM4EMAPTHSD17B10 | |
| SCHEMBL7073683 | 0.74 | F10 (0.53) | — | |
| SCHEMBL5383271 | 0.74 | ALDH1A1 (0.48) | ALDH1A1POLBKDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949550-B2 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212054-A1 | Substituted amino methyl factor Xa inhibitors | F11, F10, F9 | ALDH1A1 4288/4885POLB 3858/4885KDM4E 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.